Finasteride for BPH (Enlarged Prostate): Evidence, Dosage and Results
Medically reviewed by [Reviewer Name, MD, Urology] | Last reviewed: August 2026 | Editorial policy | Sources
Finasteride 5 mg (brand name Proscar; widely available as generic) is FDA-approved for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It works by reducing DHT — the primary driver of prostate growth — shrinking prostate volume by 20–30% and significantly reducing the risk of acute urinary retention and BPH-related surgery. Finasteride 5 mg was the first 5-alpha-reductase inhibitor approved by the FDA, receiving approval in 1992 — five years before Propecia 1 mg was approved for hair loss.
What Is BPH?
Benign prostatic hyperplasia (BPH) is a non-malignant enlargement of the prostate gland caused by progressive proliferation of epithelial and stromal cells. BPH is extremely common: it affects more than 50% of men over age 60 and more than 90% of men over 85 (Berry et al., 1984). It is the most common urologic condition in older men and one of the most common reasons for urologic referral.
BPH causes lower urinary tract symptoms (LUTS) through two mechanisms:
- Static component: Physical obstruction of the urethra by enlarged glandular tissue
- Dynamic component: Increased smooth muscle tone in the prostate and bladder neck (treated by alpha-1 blockers)
Common LUTS from BPH include: weak or intermittent urine stream, straining to urinate, urinary frequency, urgency, nocturia (waking at night to urinate), incomplete bladder emptying, and post-void dribbling. In severe cases, BPH can lead to acute urinary retention (sudden inability to urinate) — a medical emergency requiring catheterization — and repeated urinary tract infections or kidney damage.
How Finasteride Treats BPH
Dihydrotestosterone (DHT), produced from testosterone by 5-alpha-reductase Type II in the prostate, is the primary androgen driving prostate enlargement throughout adult life. Men with congenital 5-alpha-reductase Type II deficiency have essentially no BPH. Finasteride suppresses intraprostatic DHT by more than 80%, which stops the growth stimulus and allows the prostate to shrink gradually over 6–12 months.
The result: reduced prostate volume, improved urinary flow rate, lower symptom scores, and — most importantly in the long run — significantly reduced risk of complications (acute urinary retention, BPH-related surgery) compared to placebo.
Clinical Evidence: PLESS and MTOPS Trials
The PLESS Trial — 4-Year Monotherapy Data (McConnell et al., 1998)
The Proscar Long-term Efficacy and Safety Study was the pivotal 4-year, double-blind, randomized, placebo-controlled trial that supported the BPH indication. Population: n=3,040 men with symptomatic BPH and prostate volume ≥40 mL.
| Outcome at 4 Years | Finasteride 5 mg | Placebo | Benefit |
|---|---|---|---|
| Acute urinary retention events | 3.0% | 6.6% | 57% risk reduction |
| BPH-related surgery | 4.2% | 8.9% | 55% risk reduction |
| Prostate volume change | −20% (−18 mL) | +14% (+14 mL) | 34 mL absolute difference |
| Maximum urinary flow rate (Qmax) | +1.9 mL/s | +0.2 mL/s | Net gain 1.7 mL/s |
| IPSS symptom score improvement | −3.3 points | −1.3 points | 2 points greater improvement |
The MTOPS Trial — Combination Therapy Superiority (McConnell et al., 2003)
The Medical Therapy of Prostatic Symptoms trial (n=3,047 men; follow-up 4–6 years) compared finasteride 5 mg, doxazosin 8 mg (an alpha-1 blocker), combination finasteride + doxazosin, and placebo.
| Treatment Arm | Risk reduction in BPH clinical progression | AUA symptom score improvement |
|---|---|---|
| Placebo | Reference | Reference |
| Doxazosin alone | 39% reduction | Better than placebo |
| Finasteride alone | 34% reduction | Modest; more effective in larger prostates |
| Combination (doxazosin + finasteride) | 66% reduction | Superior to either monotherapy |
Key clinical implication: Finasteride monotherapy is most beneficial in men with larger prostates (≥40 mL) where the glandular (static) component is dominant. Alpha-blockers provide faster symptomatic relief (within days to weeks) and are preferred as initial monotherapy in men with smaller prostates or primarily dynamic symptoms. Combination therapy is recommended by AUA guidelines for men with moderate-to-severe symptoms and enlarged prostates (≥40 mL or PSA ≥1.5 ng/mL).
Who Is a Good Candidate for Finasteride for BPH?
| Characteristic | Finasteride appropriate? |
|---|---|
| Prostate volume ≥40 mL on ultrasound | Yes — strongest evidence in this group |
| Prostate volume <40 mL | Limited benefit; alpha-blocker monotherapy often preferred |
| PSA ≥1.5 ng/mL (AUA guideline threshold) | Yes — indicator of gland size; suggests finasteride benefit |
| Moderate-to-severe LUTS (AUA-SI ≥8) | Yes — especially combined with alpha-blocker |
| Prior acute urinary retention | Yes — finasteride significantly reduces recurrence risk |
| Prostate cancer suspicion | Evaluate first — finasteride reduces PSA 50%; cancer must be ruled out before starting |
Dosage and How Long It Takes to Work
The approved dose for BPH is finasteride 5 mg once daily, taken orally with or without food. Generic finasteride 5 mg is therapeutically equivalent to Proscar and substantially less expensive.
Unlike alpha-blockers, which relieve urinary symptoms within days to weeks, finasteride requires several months to produce meaningful symptomatic improvement:
- 1–3 months: DHT suppression established; prostate begins to shrink, but urinary flow changes are not yet apparent to most patients
- 3–6 months: Prostate volume reduction underway; some patients notice modest improvement in symptoms
- 6–12 months: Full symptomatic benefit typically established; maximum prostate volume reduction occurs by 12 months
The AUA BPH guidelines recommend assessing clinical response after a minimum of 6 months. Men who do not tolerate waiting for finasteride’s delayed onset are often started on combination therapy with an alpha-blocker from the beginning.
PSA and Prostate Cancer Monitoring
Finasteride 5 mg reduces serum PSA by approximately 50% after 6 months of treatment. This is clinically important for prostate cancer surveillance:
- Any PSA value obtained during finasteride treatment should be doubled to estimate the “untreated” PSA for cancer screening purposes
- Any confirmed increase in PSA on finasteride — even within the normal range — should be evaluated for possible prostate cancer
- Baseline PSA before starting finasteride and at 6 months (to confirm ~50% suppression) is recommended by AUA guidelines
Side Effects at the 5 mg Dose
Sexual side effects occur at higher rates with the 5 mg (BPH) dose than the 1 mg (hair loss) dose, partly because the BPH trial population was older with higher baseline rates of sexual dysfunction. From the PLESS trial:
- Erectile dysfunction: 8.1% vs. 3.7% placebo
- Decreased libido: 3.7% vs. 2.1% placebo
- Ejaculation disorder: 7.7% vs. 2.1% placebo
Most of these effects resolved in men who discontinued finasteride in the trials. The 2012 FDA label update applies to all finasteride formulations: sexual side effects may persist after discontinuation in some men.
Frequently Asked Questions
Should I take finasteride or an alpha-blocker for BPH?
Alpha-blockers (tamsulosin, doxazosin, terazosin) relieve BPH symptoms faster than finasteride and are often preferred for initial monotherapy, especially in men with smaller prostates or primarily dynamic symptoms. Finasteride is preferred — or combination therapy recommended — in men with prostate volumes ≥40 mL, elevated PSA (≥1.5 ng/mL), and/or significant risk of progression (prior urinary retention). Your urologist can assess your prostate volume, LUTS severity, and PSA to guide the best approach. Current AUA guidelines support combination therapy for moderate-to-severe LUTS with enlarged prostate.
Can finasteride shrink the prostate permanently?
No. Finasteride shrinks the prostate only while the drug is taken. Stopping finasteride allows DHT to return to pre-treatment levels; prostate volume begins to increase back toward baseline within months of stopping. The benefits on urinary flow and symptom reduction also reverse over time after discontinuation. Finasteride is a long-term management medication, not a one-time treatment.
Does finasteride affect my PSA test results for prostate cancer?
Yes, significantly. Finasteride reduces PSA by approximately 50%. Always inform your physician that you are taking finasteride before any PSA test. Your doctor should double your PSA value to estimate what it would be without finasteride treatment. Failure to account for this can result in underestimating PSA and missing a potential cancer signal. Any rise in PSA while on finasteride should be evaluated, even if the absolute value remains within the normal range.
About this page: Reviewed by [Reviewer Name, MD, Urology]. Trial data sourced from PLESS and MTOPS publications; dosing from FDA prescribing information. Last reviewed August 2026. Editorial policy.
Sources
- McConnell JD, et al. “The effect of finasteride on the risk of acute urinary retention.” N Engl J Med. 1998;338(9):557–563. (PLESS)
- McConnell JD, et al. “The long-term effect of doxazosin, finasteride, and combination therapy.” N Engl J Med. 2003;349(25):2387–2398. (MTOPS)
- Merck & Co. Proscar (finasteride 5 mg) US Prescribing Information. Revised 2022.
- Foster HE, et al. AUA Guideline on Medical Management of BPH. J Urol. 2019;202(3):592–598. (AUA 2021 update)